Clinical Trials Logo

Pathology, Molecular clinical trials

View clinical trials related to Pathology, Molecular.

Filter by:
  • None
  • Page 1

NCT ID: NCT05046366 Recruiting - Lung Cancer Clinical Trials

Development of an Artificial Intelligence System for Intelligent Pathological Diagnosis and Therapeutic Effect Prediction Based on Multimodal Data Fusion of Common Tumors and Major Infectious Diseases in the Respiratory System Using Deep Learning Technology.

Start date: October 1, 2021
Phase:
Study type: Observational

To improve accurate diagnosis and treatment of common malignant tumors and major infectious diseases in the respiratory system, we aim to establish a large medical database that includes standardized and structured clinical diagnosis and treatment information such as electronic medical records, image features, pathological features, and multi-omics information, and to develop a multi-modal data fusion-based technology system for individualized intelligent pathological diagnosis and therapeutic effect prediction using artificial intelligence technology.

NCT ID: NCT03971175 Recruiting - Clinical trials for Carcinoma, Non-Small-Cell Lung

Influence of Biopsy Technique on Moleculargenetic Tumor Characterisation in NSCLC

PROFILER
Start date: December 19, 2018
Phase: N/A
Study type: Interventional

Study design Prospective multicentre explorative randomized single blinded study to evaluate accuracy of molecular genetic characterisation of NSCLC. Patients with suspected lung cancer are randomized in a 1:1-setting for bronchoscopic tumor tissue either by forceps or by cryobiopsy. Apart from the bronchoscopic techniques liquid biopsy of peripheral blood and if feasible transbronchial needle aspiration with or without endobronchial ultrasound guidance are performed for in all patients. Objectives Primary Objective: assessment of differences in detection of molecular genetic alterations in NSCLC between bronchoscopic forceps biopsy and bronchoscopic cryobiopsy Secondary Objective: assessment of differences in detection of molecular genetic alterations in NSCLC between - liquid biopsy, solid tumor tissue by bronchoscopic techniques, cytologic material by TBNA - combination of methods (tissue biopsy, TBNA and liquid biopsy) and single techniques - naïve and processed tumor tissue specimen (eg. microdissection) To assess differences in side effects e.g. periinterventional bleeding Explorative Objective: To explore tumor mutational burden with regard to - solid tumor tissue by bronchoscopic forceps biopsy by bronchoscopic cryobiopsy - cytologic material by (EBUS-guided) TBNA - liquid biopsy Target subject population Patients with suspected lung cancer or proven NSCLC and visible tumor suspicious lesion(s) requiring tissue diagnosis form the study population of this trial.